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ABSTRACT 
Rationale:  There is epidemiological evidence that the use of acetaminophen may increase 
the risk of developing asthma.   
Objective:  To investigate the risk of asthma and other allergic disorders associated with the 
current use of acetaminophen in 13 to 14 year old children in different populations 
worldwide. 
Methods:  As part of the International Study of Asthma and Allergies in Childhood (ISAAC) 
Phase Three, 13 to 14 year old children completed written and video questionnaires, obtaining 
data on current symptoms of asthma, rhinoconjunctivitis and eczema, and a written 
environmental questionnaire obtaining data on putative risk factors including acetaminophen 
use in the past 12 months.   
Measurements:  The primary outcome measure was the odds ratio (OR) of current asthma 
symptoms associated with acetaminophen use calculated by logistic regression. 
Main results:  A total of 322,959 adolescent children from 113 centres in 50 countries 
participated.  In the multivariate analyses the recent use of acetaminophen was associated 
with an exposure-dependent increased risk of current asthma symptoms [OR 1.43 (95% CI 
1.33 to 1.53) and 2.51 (95% CI 2.33 to 2.70) for medium and high versus no use 
respectively].  Acetaminophen use was also associated with an exposure-dependent increased 
risk of current symptoms of rhinoconjunctivitis and eczema. 
Conclusions:  Acetaminophen use may represent an important risk factor for the development 
and/or maintenance of asthma, rhinoconjunctivitis and eczema in adolescent children. 
Word count:  220 
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INTRODUCTION 
 
Evidence is accumulating that the use of acetaminophen may raise the risk of developing 
asthma and that its widespread increasing use over the last 30 years may have contributed to 
the rising prevalence of asthma in different countries worldwide (1,2).  The evidence is based 
primarily on epidemiological studies which have reported that exposure to acetaminophen in 
the intrauterine environment (3-7), childhood (6,8,9) and adult life (10-13), is associated with 
an increased risk of asthma, together with one randomised controlled trial reporting increased 
rates of hospital visits for asthma in children taking acetaminophen compared with ibuprofen 
(14).  The potential mechanisms for these effects of acetaminophen include oxidant-induced 
airways inflammation and enhanced Th2 responses (1,2,15 ). 
 
Recently we have observed from Phase Three of the International Study of Asthma and 
Allergies in Childhood (ISAAC) that the reported use of acetaminophen in the first year of 
life was associated with an increased risk of current asthma symptoms in 6 to 7 year old 
children (9).  Recent acetaminophen use was also associated with a dose-dependent increased 
risk of current asthma symptoms in the 6 to 7 year old children.    ISAAC Phase Three also 
surveyed 13 to 14 year old children, which provided the opportunity of examining whether 
the associations between acetaminophen use and asthma in young children extended to 
adolescent children.  In this manuscript we report the findings from these analyses.  
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METHODS 
 
ISAAC Phase Three is a multi-centre, multi-country, cross-sectional study of two age groups 
of schoolchildren (6 to 7 year olds and 13 to 14 year olds) chosen from a random sample of 
schools in defined geographical areas within each centre (16,17).  The data for the 13 to 14 
year old children (referred to in this manuscript as adolescents) are presented in this 
manuscript.  The study instruments were two written questionnaires and a video questionnaire 
which were completed by the adolescent.  The first written questionnaire (prevalence) 
obtained data on demographic characteristics and on asthma, rhinoconjunctivitis and eczema 
symptoms. The second written questionnaire (environmental) obtained data on a wide range 
of putative protective and risk factors for the development of asthma and allergic disorders.  
The written questionnaires were translated into the local language with back-translation into 
English (18).  The video questionnaire showed different audiovisual scenes of clinical asthma. 
The complete written questionnaires and information concerning the video questionnaire can 
be found on the ISAAC website – http://isaac.auckland.ac.nz. 
 
The question relating to acetaminophen use was: 
“In the past 12 months, how often on average have you taken paracetamol (e.g. Panadol, 
Pamol)?”   Never/At least once a year/At least once per month. 
Adolescents in the 1+ per year (medium) and 1+ per month (high) categories were compared 
to those in the “never” category . 
A participant was considered to have current asthma symptoms (current wheeze) if they 
provided a positive response to the written question “Have you had wheezing or whistling in 
the chest in the past 12 months?”  
A participant was considered to have current symptoms of rhinoconjunctivitis if they provided 
positive responses to both these written questions: 
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“In the past 12 months have you had a problem with sneezing or a runny or blocked nose 
when you DID NOT have a cold or the flu?”  If yes, “In the past 12 months has this nose 
problem been accompanied by itchy watery eyes?”  
A participant was considered to have current symptoms of eczema if they provided positive 
responses to both these written questions: 
“Have you ever had this itchy rash at any time in the past 12 months?”  If yes, “Has this 
itchy rash at any time affected any of the following places – the folds of the elbows, behind the 
knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes?”  (These 
questions were preceded by the question “Have you ever had an itchy skin rash which was 
coming and going for at least 6 months?”) 
 Symptoms of severe asthma were defined by the responses to the following written 
questions: 
(1) “How many attacks of wheezing have you had in the past 12 months?”   None/1 to 3/4 to 
12/More than 12.  Participants who reported 4 or more attacks were considered to have 
symptoms of severe asthma. 
(2) “In the past 12 months how often, on average, has your sleep been disturbed due to 
wheezing?”   Never woken with wheezing/Less than one night per week/One or more nights 
per week.  A response of 1 or more nights per week was considered to indicate symptoms of 
severe asthma. 
(3) “In the past 12 months, has the wheezing ever been severe enough to limit your speech to 
only one or two words at a time between breaths?”   Yes/No.  A positive response was 
considered to indicate symptoms of severe asthma. 
For the video questionnaire, participants viewed five scenes of clinical asthma and were asked 
to indicate whether they had experienced similar symptoms “ever”, if yes, “in the past year”.  
A participant was considered to have current wheeze (video) if they provided a positive 
response “in the past year” to the first scene, showing a person wheezing at rest. 
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Adherence to the protocol was assessed by the ISAAC International Data Centre and centres 
with serious discrepancies were excluded. 
 
Analysis 
To be included in the analysis, centres were required to have studied at least 1000 children 
and have a response rate of >70%.  Odds ratios (ORs) were calculated using generalised linear 
mixed models with a binomial distribution and logit link and with centres being modelled as a 
random effect.  The analyses on all study participants were adjusted for sex, region of the 
world, language and gross national income as previously described (9). 
 
Multivariate analyses were conducted to investigate whether the association between 
symptoms and acetaminophen use were confounded by other variables in the environmental 
questionnaire.  For inclusion in these analyses, centres were required to have at least 70% data 
available for all covariates; subjects who had a missing value for any of the covariates were 
removed.  The covariates included in the multivariate analyses were maternal education, 
current maternal smoking, siblings, current consumption of vegetables and fruit as previously 
described. 
 
The primary outcome measure was the association between current acetaminophen use and 
current asthma symptoms, expressed as the odds ratios (medium versus none, high versus 
none), as determined by multivariate analysis. 
 
Conditional analyses were also undertaken in which the odds ratios were calculated, for the 
risk of rhinoconjunctivitis or eczema, associated with acetaminophen use, in those who did 
not report wheezing in the past 12 months. 
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The population attributable risk of current symptoms due to each acetaminophen use measure 
was calculated using the Mantel-Haenszel approach using the adjusted relative risk and the 
proportion of the participants who were exposed. This calculation method makes the 
‘homogeneity’ assumption (19). 
 
All analyses were carried out using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA). 
 
Ethics approval 
All participating centres obtained local ethics approval. 
 
The role of the funding sources 
The funders of the study had no role in study design; in the collection, analysis, and 
interpretation of data; in writing of the report; or in the decision to submit the paper for 
publication. 
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RESULTS 
 
There were 361,598 13 to 14 year old adolescents from 122 centres in 54 countries who 
completed the Phase Three environmental questionnaire (Figure 1).  Nine centres were 
excluded because they did not include the acetaminophen question or had <70% data for 
current acetaminophen use.  Participants with missing data for gender or current 
acetaminophen use were excluded at this stage.  These exclusions resulted in 322,959 
adolescents from 113 centres in 50 countries contributing data to the analyses presented.  
Following the exclusion of centres in which there was <70% data for any covariate, and of 
participants for whom there was missing data for any covariate, there were 180,887 
adolescents from 77 centres in 36 countries included in the multivariate analyses. 
 
The mean percentage of children exposed to acetaminophen at least once a month was 30%, 
with levels ranging from 2% in Taiwan to 68% in Nigeria (Figure 2a).  The mean percentage 
of children exposed to acetaminophen at least once in the previous 12 month period was 73%, 
ranging from 41% in China and 92% in Panama.   
 
Asthma 
The reported use of acetaminophen in the past 12 months was associated with a significant 
exposure-dependent increased risk of current asthma symptoms (Table 1).  In the adjusted 
analyses, the odds ratios for current asthma symptoms for medium (1+ per year) and high (1+ 
per month) acetaminophen use compared with no use were 1.38 (95% CI 1.31 to 1.46) and 
2.36 (95% CI 2.24 to 2.50) respectively.  In the multivariate analyses the odds ratios for 
current asthma symptoms for medium and high acetaminophen use compared with no use 
were 1.43 (95% CI 1.33 to 1.53) and 2.51 (95% CI 2.33 to 2.70) respectively.  The exposure-
dependent increased risk of current asthma symptoms with acetaminophen use was present 
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throughout the major regions of the world (Table 2, Figure 2).  The population attributable 
risk for asthma symptoms associated with current acetaminophen use was 41%. 
 
The reported current use of acetaminophen was associated with a significant exposure-
dependent increased risk of current wheeze (video) (Table 1, Figure 2).  The reported current 
use of acetaminophen was associated with a significantly increased risk of symptoms of 
severe asthma (Table 1, Figure 2).  The magnitude of the increased risks of current wheeze 
(video) and symptoms of severe asthma were similar to those for current wheeze.  The 
population attributable risk for symptoms of severe asthma due to current acetaminophen use 
was 43%. 
 
Rhinoconjunctivitis and eczema 
The reported use of acetaminophen in the past 12 months was associated with a significant 
dose-dependent increased risk of current symptoms of rhinoconjunctivitis and eczema (Table 
3).  The risk was observed in most regions of the world (Table 4, Figure 3).  The population 
attributable risk for current symptoms of rhinoconjunctivitis and eczema, associated with 
current acetaminophen use was 36% and 40% respectively. 
 
When participants with current wheeze were excluded from the multivariate analysis, the use 
of acetaminophen was associated with a significantly increased risk of current symptoms of 
rhinoconjunctivitis with odds ratios of 1.33 (95% CI 1.25 to 1.42) and 2.18 (95% CI 2.04 to 
2.33) for medium and high acetaminophen use respectively.  Likewise, when participants with 
current wheeze were excluded from the analysis, there was an increased risk of current 
symptoms of eczema associated with the use of acetaminophen with odds ratios of 1.32 (95% 
CI 1.21 to 1.44) and 1.87 (95% CI 1.7 to 2.05) for medium and high acetaminophen use 
respectively.  Similar estimates of risk were observed when participants with asthma ever 
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were excluded from the multivariate analysis, for both current symptoms of 
rhinoconjunctivitis and symptoms of eczema (Online Supplement). 
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DISCUSSION 
 
This study has identified that the reported use of acetaminophen in 13 to 14 year old 
adolescent children was associated with an exposure-dependent increased risk of asthma 
symptoms.  The association was present in all major regions of the world and persisted in the 
multivariate analyses which controlled for confounding variables.  The magnitude of the 
association was substantial with a 2.5-fold increased risk associated with frequent 
acetaminophen use, at least once per month.  Similar magnitudes of risk were observed with 
symptoms of severe asthma determined by written questionnaire and with current wheeze 
when assessed by video questionnaire, both measures of clinically significant asthma (20-23).  
The public health significance of the findings is suggested by the population attributable risk 
for symptoms of severe asthma due to acetaminophen of 43%.  Significant associations were 
also observed between current acetaminophen use and the risk of the related conditions 
rhinoconjunctivitis and eczema. 
 
These findings extend our previous observations from ISAAC Phase Three, that the use of 
acetaminophen in infancy and current use was associated with an increased risk of asthma 
symptoms in 6 to 7 year old children.  While many of the methodological issues relating to 
the earlier study also apply to analyses in the 13 to 14 year old age group, there are also some 
differences which are relevant to the interpretation of the study findings.  Firstly, the current 
study had greater power and worldwide representation, with around 320,000 adolescents from 
113 centres in 50 countries, compared with around 200,000 6 to 7 year old children from 73 
centres in 31 countries. Secondly, we utilised a video questionnaire in which the audiovisual 
presentation of clinical asthma in different situations was presented.  Validation studies have 
shown that the video questionnaire has high sensitivity and specificity for identifying children 
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with bronchial hyperresponsiveness, providing data relatively free from bias due to language 
and culture (20-22).  
 
Confounding by indication represented the most important consideration in the interpretation 
of the primary 6 to 7 year old ISAAC study findings of acetaminophen use in infancy (24-27).  
Indeed, since publication of the earlier ISAAC findings, there have been a number of reports 
from prospective cohort studies that the association between acetaminophen use in early life 
and the risk of asthma in later childhood could be explained by confounding, due to the close 
association between acetaminophen use and respiratory morbidity in early childhood (28-30).  
While such confounding is less likely to be relevant to the current use of acetaminophen in 
adolescent children, it may still be present to some extent.  Another possibility is that there 
could be confounding by reverse causation if adolescents with asthma were more likely to 
develop febrile illnesses or experience pain, and as a result have greater acetaminophen use 
than non-affected adolescents.  There does not appear to be data to assess this proposition for 
the wide range of febrile illnesses affecting adolescents worldwide although those with 
asthma may be more prone to migraine for which acetaminophen may be prescribed (31).  
However, there is evidence that acetaminophen may cause greater nasal symptoms and signs, 
and a reduced serum neutralising antibody response when taken for rhinovirus infection (32).  
This observation is relevant both to our study findings, and consideration of the nature of the 
association between acetaminophen use for respiratory tract infections in infancy and 
development of asthma in later childhood. 
  
Another consideration is that in many countries, acetaminophen is marketed as the preferred 
analgesic and antipyretic of choice in persons with asthma.  Although this has the potential to 
result in preferential use of acetaminophen, the observation that the association was present in 
populations with widely differing lifestyles, standard of living, medical practice and 
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availability of information of over-the-counter products containing acetaminophen suggests 
that it may not have had a major contribution to the association observed.  
 
It is likely that adolescents who frequently took acetaminophen were more likely to have 
received acetaminophen in earlier childhood and the risk of asthma may have been due to this 
earlier use.  This cannot be assessed in our study as only information on current use of 
acetaminophen was obtained, although it is relevant that in the previous ISAAC analysis the 
risk of current use of acetaminophen in 6 to 7 year old children existed independently of 
acetaminophen use in the first year of life, and vice versa.  
 
Potential confounding by factors that influence the risk of developing childhood asthma and 
use of acetaminophen is inherent in cross-sectional population-based studies.  To address this 
issue, the odds ratios were adjusted for centre level factors such as region of the world, 
language and gross national income, and multivariate analyses were undertaken in which 
potential confounding factors at the individual level were controlled for.  In the multivariate 
analyses, there was no reduction in the strength of the association between acetaminophen use 
and asthma, suggesting that there was no major confounding by these factors.  This pattern 
differs from that observed in the analyses from the 6 to 7 year old children, in which the 
strength of the association was reduced in multivariate analyses, suggesting that confounding 
was present. 
 
With these considerations in mind we propose that the findings are consistent with the cross-
sectional and longitudinal epidemiological studies which have reported that acetaminophen 
exposure in the intrauterine environment, throughout childhood, and in adult life is associated 
with an increased risk of asthma (1-16).  The findings are also consistent with the one 
randomised controlled trial of acetaminophen use in asthmatic children (14).  In that study, 
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asthmatic children were randomly assigned to receive either acetaminophen or ibuprofen 
during a febrile illness.  Children randomised to acetaminophen had an increased risk of an 
outpatient visit for asthma, an effect which was observed for the treatment of fever due to 
respiratory but not other infective causes.  However, as the study did not include a placebo 
treatment it was not possible to determine whether the observed difference in morbidity was 
attributable to an increased risk with acetaminophen treatment or a decreased risk with 
ibuprofen. 
 
Our findings complement the international ecological analyses based on data from countries 
that participated in ISAAC Phase One and the European Community Respiratory Health 
Survey in which a positive association between per capita consumption and acetaminophen 
and the prevalence of asthma in children and adults respectively was reported (33).  An 
observation from these studies is that English-speaking countries, which have amongst the 
highest prevalence rates of asthma, also have amongst the highest acetaminophen use, 
suggesting that greater acetaminophen use may explain to some extent the higher prevalence 
of asthma in English-speaking countries. 
 
Overall, the population attributable risks for current symptoms of asthma and symptoms of 
severe asthma were around 40%, suggesting that if the associations were causal, they would 
be of major public health significance.  These compare with the population attributable risks 
of around 30% in the previous ISAAC study of 6 to 7 year old children. 
 
Similar to the findings in 6 to 7 year old children we observed an association between current 
acetaminophen use and current rhinoconjunctivitis and eczema symptoms in 13 to 14 year old 
adolescents, and that this association was independent of the presence of asthma.  These 
observations suggest that acetaminophen may have systemic inflammatory effects, possibly 
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through increasing oxygen stress resulting from depletion of glutathione-dependent enzymes, 
which may also lead to enhanced TH2 allergic immune responses (1,2,15).  Both mechanisms 
could lead to greater allergic inflammation, resulting in the development or worsening of pre-
existing asthma, rhinoconjunctivitis or eczema, depending on the organ systems affected.  
Furthermore, acetaminophen may suppress the immune response to, and prolong the 
symptomatic illness from rhinovirus infections (32), which are a common cause of severe 
exacerbations of asthma in childhood (34), and adult life (35), and in infancy are associated 
with an increased risk of subsequent asthma (36).  Similarly, a recent study of prophylactic 
acetaminophen given at the time of vaccination illustrates that acetaminophen in routine 
antipyretic doses is capable of modulating immune responses (37). 
 
In conclusion, the study findings add to the evidence that acetaminophen use in childhood 
may be an important risk factor for the development and/or maintenance of asthma.  
However, it is not possible in a study of this design to determine whether the positive 
association observed was causal. As a result, randomised controlled trials are now urgently 
required to investigate this relationship further and to guide the use of antipyretics, not only in 
children, but also in pregnancy and adult life.  
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ISAAC Phase Three Study Group 
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Utrecht, Netherlands); J Crane (Wellington Asthma Research Group, Wellington School of 
Medicine, New Zealand); P Ellwood (Department of Paediatrics, Faculty of Medical and 
Health Sciences, The University of Auckland, New Zealand); C Flohr (Centre for Evidence 
Based Dermatology, Queen’s Medical Centre, University Hospital, Nottingham, UK); F 
Forastiere (Department of Epidemiology, Rome E Health Authority, Italy); L García-Marcos 
(Instituto de Salud Respiratoria, Universidad de Murcia, Spain); S Foliaki* (Centre for Public 
Health Research, Massey University, Wellington, New Zealand); U Keil* (Institut für 
Epidemiologie und Sozialmedizin, Universität Münster, Germany); CKW Lai* (Department 
of Medicine and Therapeutics, The Chinese University of Hong Kong, SAR China); J Mallol* 
(Department of Respiratory Medicine, University of Santiago de Chile, Chile); CF Robertson 
(Murdoch Children’s Research Institute, Melbourne, Australia); EA Mitchell (Department of 
Paediatrics, Faculty of Medical and Health Sciences, The University of Auckland, New 
Zealand); S Montefort* (Department of Medicine, University of Malta, Malta), J Odhiambo* 
(Centre Respiratory Diseases Research Unit, Kenya Medical Research Institute, Nairobi, 
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Medical School, London, UK); E von Mutius (Dr von Haunerschen Kinderklinik de 
Universität München, Germany); SK Weiland† (Department of Epidemiology, University of 
Ulm, Germany); G Weinmayr (Institute of Epidemiology, University of Ulm, Germany); H 
Williams (Centre for Evidence Based Dermatology, Queen’s Medical Centre, University 
Hospital, Nottingham, UK); G Wong (Department of Paediatrics, Prince of Wales Hospital, 
Hong Kong, SAR China). *Regional Coordinators. †Deceased March 2007. 
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Department of Paediatrics: Child and Youth Health, and AW Stewart, School of Population 
Health, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand. 
ISAAC Principal Investigators: Barbados: Dr ME Howitt* (Barbados); Belgium: Prof J 
Weyler (Antwerp); Bolivia: Dr R Pinto-Vargas* (Santa Cruz); Brazil: Assoc Prof AJLA 
Cunha (Nova Iguaçu), Assoc Prof L de Freitas Souza (Feira de Santana, Salvador, Vitória da 
Conquista); Cameroon: Prof C Kuaban* (Yaounde); Canada: Prof A Ferguson (Vancouver); 
Channel Islands: Dr P Standring (Guernsey); Chile: Dr P Aguilar (South Santiago), Dr L 
Amarales (Punta Arenas), Dr LAV Benavides (Calama), Dra A Contreras (Chiloe); China: 
Prof Y-Z Chen* (Beijing, Tong Zhou), Assis Prof O Kunii (Tibet), Dr Q Li Pan (Wulumuqi), 
Prof N-S Zhong (Guangzhou); Colombia: Dr G Aristizábal (Bogotá), Dr AM Cepeda 
(Barranquilla), Dr GA Ordoñez (Cali); Cote d'Ivoire: Dr BN Koffi* (Urban Cote d'Ivoire); 
Ecuador: Dr C Bustos (Guayaquil); Estonia: Dr M-A Riikjärv* (Tallinn); Ethiopia: Assoc 
Prof K Melaku (Addis Ababa); Fiji: Dr R Sa'aga-Banuve (Suva); Finland: Dr J Pekkanen* 
(Kuopio County); Former Yugoslav Republic of Macedonia (FYROM): Dr E Vlaski* 
(Skopje); Gabon: Dr IE Hypolite* (Port-Gentil); Hong Kong: Prof YL Lau (Hong Kong, 6-7 
year age group), Prof G Wong (Hong Kong, 13-14 year age group); Hungary: Dr Z Novák 
(Szeged), Dr G Zsigmond* (Svábhegy); India: Prof S Awasthi (Lucknow), Assoc Prof S 
Bhave (Rasta Peth), Dr NM Hanumante (Pune), Dr KC Jain (Jodhpur), Dr VA Khatav 
(Borivali), Dr SN Mantri (Mumbai (29)), Dr AV Pherwani (Mumbai (18)), Prof S Rego 
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(Bangalore), Prof M Sabir (Bikaner), Dr S Salvi (Nagpur, Pimpri), Dr G Setty (Chennai (3)), 
Prof SK Sharma (New Delhi (7)), Prof V Singh (Jaipur), Dr TU Sukumaran (Kottayam), Dr 
PS Suresh Babu (Davangere); Indonesia: Prof Dr CB Kartasasmita (Bandung), Prof P 
Konthen (Bali), Dr W Suprihati (Semarang); Iran: Dr M-R Masjedi* (Rasht, Tehran); Japan: 
Dr H Odajima (Fukuoka); Kuwait: Dr JA al-Momen (Kuwait); Kyrgyzstan: Dr C Imanalieva* 
(Balykchi, Bishkek); Lithuania: Assoc Prof J Kudzyte* (Kaunas); Malaysia: Assoc Prof BS 
Quah (Kota Bharu), Dr KH Teh (Alor Setar); Mexico: Dr M Baeza-Bacab* (Mérida), Dra M 
Barragán-Meijueiro (Ciudad de México (3)), Dra BE Del-Río-Navarro (Ciudad de México 
(1)), Dr R García-Almaráz (Ciudad Victoria), Dr SN González-Díaz (Monterrey), Dr JV 
Merida-Palacio (Mexicali Valley), Dra N Ramírez-Chanona (Ciudad de México (4)), Dr S 
Romero-Tapia (Villahermosa); Morocco: Prof Z Bouayad* (Boulmene, Casablanca, 
Marrakech); New Zealand: Prof MI Asher* (Auckland), Dr R MacKay (Nelson), Dr C Moyes 
(Bay of Plenty), Assoc Prof P Pattemore (Christchurch), Prof N Pearce (Wellington); Nigeria: 
Prof BO Onadeko (Ibadan); Panama: Dr G Cukier* (David-Panamá); Peru: Dr P Chiarella* 
(Lima); Philippines: Prof F Cua-Lim* (Metro Manila); Poland: Assoc Prof A Brêborowicz 
(Poznan), Assoc Prof G Lis* (Kraków); Portugal: Dra R Câmara (Funchal), Dr JM Lopes dos 
Santos (Porto), Dr C Nunes (Portimao), Prof JE Rosado Pinto* (Lisbon); Samoa: Ms P 
Fuimaono (Apia); South Africa: Prof HJ Zar* (Cape Town); South Korea: Prof H-B Lee* 
(Provincial Korea, Seoul); Spain: Prof A Blanco-Quirós (Valladolid), Dr RM Busquets 
(Barcelona), Dr I Carvajal-Urueña (Asturias), Dr G García-Hernández (Madrid), Prof L 
García-Marcos* (Cartagena), Dr C González Díaz (Bilbao), Dr A López-Silvarrey Varela (A 
Coruña), Prof MM Morales-Suárez-Varela (Valencia), Prof EG Pérez-Yarza (San Sebastián); 
Sudan: Prof OAA Musa (Khartoum); Sultanate of Oman: Assoc Prof O Al-Rawas* (Al-
Khod); Syrian Arab Republic: Dr S Mohammad* (Tartous), Prof Y Mohammad (Lattakia), Dr 
K Tabbah (Aleppo); Taiwan: Dr J-L Huang* (Taipei), Dr C-C Kao (Taoyuan); Tokelau: Dr T 
Iosefa* (Tokelau); USA: Dr HH Windom (Sarasota); United Kingdom: Dr M Burr (Wales); 
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Uruguay: Dra D Holgado* (Montevideo), Dra MC Lapides (Paysandú); Venezuela: Dr O 
Aldrey* (Caracas). 
ISAAC National Coordinators not identified above: Brazil: Prof D Solé; Canada: Prof M 
Sears; Chile: Dra V Aguirre; Colombia (interim): Prof J Mallol; Ecuador: Dr S Barba; Hong 
Kong: Dr CKW Lai; India: Dr J Shah; Isle of Man: Prof R Anderson; Japan: Prof S Nishima; 
Malaysia: Assoc Prof J de Bruyne; Samoa: Dr N Tuuau-Potai; Sudan: Dr A El Sony. 
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Table 1:  The association between acetaminophen use in past 12 months§ and asthma symptoms 
Odds Ratio (95% CI) 
Adjusted* 
(all children) 
Adjusted# 
(children with complete covariate data) 
Multivariate Analysis† 
(children with complete covariate data) 
  
Number of 
Participants 
With Each 
Symptom‡ 
Medium 
vs. Never 
High 
vs. Never 
Medium 
vs. Never 
High vs. 
Never 
Medium 
vs. Never 
High 
vs. Never 
 
Current wheeze 
 
35,146 
 
1.38 
(1.31 to 1.46) 
 
2.36 
(2.24 to 2.50) 
 
1.42 
(1.34 to 1.52) 
 
2.47 
(2.31 to 2.64) 
 
1.43 
(1.33 to 1.53) 
 
2.51 
(2.33 to 2.70) 
Current wheeze 
(video) 
18,528 1.29 
(1.20 to 1.39) 
2.15 
(2.00 to 2.32) 
1.33 
(1.22 to 1.45) 
2.29 
(2.10 to 2.51) 
1.36 
(1.24 to 1.49) 
2.35 
(2.13 to 2.60) 
Severe asthma 17,199 1.25 
(1.17 to 1.34) 
2.50 
(2.34 to 2.68) 
1.29 
(1.19 to 1.39) 
2.67 
(2.47 to 2.88) 
1.33 
(1.22 to 1.45) 
2.75 
(2.52 to 3.00) 
Asthma ever 37,355 1.23 
(1.17 to 1.28) 
1.81 
(1.73 to 1.90) 
1.24 
(1.18 to 1.31) 
1.87 
(1.77 to 1.98) 
1.24 
(1.17 to 1.31) 
1.88 
(1.77 to 1.99) 
 
§  Current acetaminophen use: high – 1+/month in past 12 months; medium – 1+ in past 12 months; never – none in past 12 months. 
 Current wheeze: wheeze in the past 12 months (written questionnaire). 
 Current wheeze (video): wheeze in the past 12 months (video questionnaire). 
 Severe asthma symptoms: sleep disturbed due to wheezing on average 1 or more nights per week, or wheezing severe enough to limit speech, or 4 or 
more attacks of wheezing in the past 12 months. 
‡ Adjusted analysis. 
* Adjusted for sex, region of the world, language and gross national income.  A total of 322,959 children were included from 113 centres in 50 
countries. For current wheeze (video), a total of 253,280 children were included from 89 centres in 37 countries. 
# Adjusted for sex, region of the world, language and gross national income.  Analysis restricted to the centres included in the multivariate analyses. 
† Multivariate analysis including centres with at least 70% data available for all covariates.  All children who had a missing value for any of the 
covariates have been removed.  Covariates included maternal education, maternal smoking, current diet, siblings.  A total of 180,887 children were 
included from 77 centres in 36 countries. For current wheeze (video), a total of 140,059 children were included from 60 centres in 28 countries. 
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Table 2:  The association between acetaminophen use in the past 12 months# and current symptoms of asthma in different regions of the world 
Odds Ratio (95% CI)†  Countries 
(Number) 
Centres 
(Number) 
Subjects 
(Number) 
Current Wheeze
(Number) Medium vs. Never High vs. Never 
Africa 6 6 12,285 1,635 1.03 (0.74, 1.45) 1.20 (0.88, 1.65) 
Asia-Pacific 5 8 24,405 1,412 1.54 (1.32, 1.80) 2.11 (1.65, 2.68) 
Eastern Mediterranean 3 6 12,970 1,038 1.69 (1.07, 2.67) 2.60 (1.68, 4.02) 
Indian Subcontinent 1 12 26,345 1,305 1.20 (0.91, 1.58) 2.71 (2.05, 3.58) 
Latin America 10 18 41,136 6,794 1.36 (1.19, 1.55) 2.35 (2.05, 2.68) 
North America 3 3 5,741 1,007 1.09 (0.78, 1.53) 2.12 (1.52, 2.96) 
Northern & Eastern Europe 5 7 18,860 1,486 1.37 (1.15, 1.64) 2.67 (2.16, 3.31) 
Oceania 1 4 8,796 2,227 2.00 (1.42, 2.82) 3.74 (2.67, 5.23) 
Western Europe 2 13 30,349 3,723 1.74 (1.45, 2.08) 3.18 (2.64, 3.82) 
 
# Current acetaminophen use: high – 1+/month in past 12 months; medium – 1+ in past 12 months; never – none in past 12 months. 
† Multivariate analysis included centres with at least 70% data available for all covariates.  All children who had a missing value for any of the 
covariates have been removed.  Covariates included maternal education, maternal smoking, current diet, siblings.  Adjusted for sex, region of the 
world, language and gross national income.  A total of 180,887 children were included from 77 centres in 36 countries. 
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Table 3:  The association between acetaminophen use in the past 12 months§ and current symptoms of rhinoconjunctivitis and eczema 
Odds Ratio (95% CI) 
Adjusted* 
(all children) 
Adjusted# 
(children with complete covariate data) 
Multivariate Analysis† 
(children with complete covariate data) 
  
Number of 
Participants 
With Each 
Symptom‡ 
Medium 
vs. Never 
High 
vs. Never 
Medium 
vs. Never 
High 
vs. Never 
Medium 
vs. Never 
High 
vs. Never 
 
Rhinoconjunctivitis 
 
45,017 
 
1.34 
(1.28 to 1.40) 
 
2.23 
(2.13 to 2.35) 
 
1.38 
(1.31 to 1.47) 
 
2.40 
(2.26 to 2.55) 
 
1.38 
(1.29 to 1.47) 
 
2.39 
(2.24 to 2.55) 
 
Eczema 22,134 1.28 
(1.20 to 1.36) 
1.90 
(1.78 to 2.03) 
1.31 
(1.22 to 1.41) 
1.97 
(1.82 to 2.12) 
1.31 
(1.21 to 1.42) 
1.99 
(1.82 to 2.16) 
 
§ Current acetaminophen use: high – 1+/month in past 12 months; medium – 1+ in past 12 months; never – none in past 12 months. 
‡ Adjusted analysis. 
* Adjusted for sex, region of the world, language and gross national income.  A total of 322,959 children were included from 113 centres in 50 
countries. 
# Adjusted for sex, region of the world, language and gross national income.  Analysis restricted to the centres included in the multivariate analyses. 
† Multivariate analysis including centres with at least 70% data available for all covariates.  All children who had a missing value for any of the 
covariates have been removed.  Covariates included maternal education, maternal smoking, current diet, siblings.  A total of 180,887 children were 
included from 77 centres in 36 countries. 
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Table 4:  The dose-dependent association between acetaminophen use in the past 12 months# and current symptoms of rhinoconjunctivitis and eczema 
in different regions of the world 
Rhinoconjunctivitis Eczema 
Odds Ratio (95% CI) † Odds Ratio (95% CI) † 
 
Current 
Rhinoconjunctivitis
(Number) Medium vs. Never High vs. Never 
Current Eczema
(Number) Medium vs. Never High vs. Never 
Africa 2,055 1.30 (1.01, 1.67) 1.38 (1.07, 1.78) 1,787 1.45 (1.14, 1.85) 1.30 (1.01, 1.67) 
Asia-Pacific 3,096 1.40 (1.23, 1.60) 1.95 (1.54, 2.45) 881 1.29 (1.07, 1.56) 1.57 (1.19, 2.06) 
Eastern Mediterranean 1,419 1.31 (0.92, 1.85) 2.14 (1.55, 2.97) 547 1.82 (1.09, 3.02) 2.34 (1.44, 3.81) 
Indian subcontinent 1,987 1.40 (1.12, 1.75) 2.29 (1.82, 2.89) 793 1.05 (0.80, 1.38) 1.78 (1.34, 2.38) 
Latin America 7,793 1.36 (1.19, 1.56) 2.41 (2.11, 2.76) 4,425 1.28 (1.07, 1.53) 2.09 (1.75, 2.49) 
North America 877 1.14 (0.84, 1.54) 2.17 (1.61, 2.92) 438 1.41 (0.90, 2.21) 1.95 (1.23, 3.09) 
Northern & Eastern Europe 1,815 1.50 (1.27, 1.76) 2.52 (2.08, 3.06) 1,080 1.27 (1.04, 1.55) 1.87 (1.47, 2.38) 
Oceania 1,471 1.15 (0.84, 1.59) 2.38 (1.75, 3.24) 683 1.26 (0.74, 2.16) 1.77 (1.05, 3.00) 
Western Europe 4,352 1.53 (1.29, 1.80) 2.87 (2.42, 3.40) 1,378 1.56 (1.25, 1.93) 2.67 (2.14, 3.33) 
 
# Current acetaminophen use: high – 1+/month in past 12 months; medium – 1+ in past 12 months; never – none in past 12 months. 
† Multivariate analysis included centres with at least 70% data available for all covariates.  All children who had a missing value for any of the 
covariates have been removed.  Covariates included maternal education, maternal smoking, current diet, siblings.  Adjusted for sex, region of the 
world, language and gross national income.  A total of 180,887 children were included from 77 centres in 36 countries. 
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FIGURE LEGENDS 
 
Figure 1: 
Flow diagram of inclusion of children, centres and countries. 
 
Figure 2: 
Plot showing the odds ratios for the association between the reported use of acetaminophen in 
the past 12 months (at least once a month versus none) and current wheeze (A), current 
wheeze (video) (B), and severe asthma symptoms (C) in 13 to 14 year old children.  The dots 
(z) represent the odds ratios for each of the 77 centres in 36 countries; the square () 
represents the global odds ratio.  For every country, the percentage of children exposed to 
acetaminophen (at least once a month) is stated in brackets. 
 
Figure 3: 
Plot showing the odds ratios for the association between the reported use of acetaminophen in 
the past 12 months (at least once a month versus none) and current symptoms of 
rhinoconjunctivitis (A) and eczema (B) in 13 to 14 year old children.  The dots (z) represent 
the odds ratios for each of the 77 centres in 36 countries; the square () represents the global 
odds ratio.  For each country, the percentage of children exposed to acetaminophen (at least 
once a month) is stated in brackets. 
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Figure 1: 
ISAAC Phase Three Environmental 
Questionnaire analysis 
Children aged 13-14 years 
• 361,598 children 
• 122 centres 
• 54 countries 
  
    
  
 
Excluded: 
• Centres which did not include the 
acetaminophen question in the 
environmental questionnaire 
• Centres with <70% data for 
acetaminophen use 
• Participants with missing data for 
acetaminophen use or gender 
(9 centres; 4 countries; 38,639 children) 
    
Current acetaminophen use: adjusted 
analyses 
• 322,959 children 
• 113 centres 
• 50 countries 
  
    
  
 
Excluded: 
• Centres with <70% data for any covariate 
• Participants with missing data for any 
covariate 
(36 centres; 14 countries; 142,072 children) 
    
Current acetaminophen use: adjusted 
and multivariate analyses 
• 180,887 children 
• 77 centres 
• 36 countries 
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Figure 2A: 
 
 
Taiwan (2%) zz
China (4%) z z
Former Yugoslav Republic of Macedonia (FYROM) (7%) z
Hong Kong (7%) z
Lithuania (10%) z
Hungary (10%) zz
Estonia (13%) z
Uruguay (22%) z z
Canada (23%) z
India (24%) zzzzz z zz z zz
Philippines (24%) z
Ethiopia (25%) z
Brazil (26%) zz zz
Portugal (29%) zzzz
Peru (29%) z
Poland (30%) z z
Panama (30%) z
Indonesia (30%) zz
Mexico (30%) zz
Spain (31%) z z zzz zz
Ecuador (32%) z
South Africa (36%) z
Venezuela (36%) z
Chile (40%) z zz
USA (42%) z
Syrian Arab Republic (43%) zz z
Morocco (45%) z
Bolivia (47%) z
New Zealand (48%) zz zz
Gabon (51%) z
Barbados (51%) z
Iran (52%) z
Colombia (54%) zz
Kuwait (57%) z
Cameroon (66%) z
Nigeria (68%) z
Odds Ratio
0.50 1.0 2.0 4.0 8.0
Country (% frequent acetaminophen use)
Global Total (30%)
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Figure 2B: 
 
Taiwan (2%) zz
China (4%) z
Hong Kong (7%) z
Lithuania (10%) z
Hungary (11%) zz
Estonia (13%) z
Uruguay (22%) z z
India (23%) zz zzzz z zz z
Philippines (24%) z
Brazil (28%) zz
Peru (29%) z
Indonesia (30%) zz
Mexico (30%) zz
Spain (31%) zzzz zz z
Ecuador (32%) z
Portugal (34%) z
South Africa (36%) z
Chile (41%) z z
USA (43%) z
Syrian Arab Republic (43%) zz z
Morocco (45%) z
Bolivia (47%) z
New Zealand (48%) zz zz
Colombia (51%) z
Barbados (51%) z
Iran (52%) z z
Kuwait (57%) z
Nigeria (69%) z
Odds Ratio
0.50 1.0 2.0 4.0 8.0
Country (% f requent acetaminophen use)
Global Total (29%)
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Figure 2C: 
 
Taiwan (2%) zz
China (4%) z z
Former Yugoslav Republic of Macedonia (FYROM) (7%) z
Hong Kong (7%) z
Lithuania (10%) z
Hungary (10%) zz
Estonia (13%) z
Uruguay (22%) z z
Canada (23%) z
Philippines (24%) z
India (24%) zzz z z zz z
Ethiopia (25%) z
Brazil (26%) zzz
Portugal (29%) z zz z
Peru (29%) z
Poland (30%) zz
Panama (30%) z
Indonesia (30%) zz
Mexico (30%) zz
Spain (31%) zzzz zz z
Ecuador (32%) z
South Africa (36%) z
Venezuela (36%) z
Chile (40%) z zz
USA (42%) z
Syrian Arab Republic (43%) z zz
Morocco (45%) z
Bolivia (47%) z
New Zealand (48%) zzz z
Gabon (51%) z
Barbados (51%) z
Iran (52%) zz
Colombia (54%) zz
Kuwait (57%) z
Cameroon (66%) z
Nigeria (68%) z
Odds Ratio
0.50 1.0 2.0 4.0 8.0 16.0
Country (% frequent acetaminophen use)
Global Total (30%)
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Figure 3A: 
 
Taiwan (2%) zz
China (4%) z z
Former Yugoslav Republic of Macedonia (FYROM) (7%) z
Hong Kong (7%) z
Lithuania (10%) z
Hungary (10%) zz
Estonia (13%) z
Uruguay (22%) zz
Canada (23%) z
India (24%) zzz z zzz zz
Philippines (24%) z
Ethiopia (25%) z
Brazil (26%) zzz
Portugal (29%) z zzz
Peru (29%) z
Poland (30%) zz
Panama (30%) z
Indonesia (30%) z z
Mexico (30%) zz
Spain (31%) z zz zz z
Ecuador (32%) z
South Africa (36%) z
Venezuela (36%) z
Chile (40%) zz
USA (42%) z
Syrian Arab Republic (43%) zz z
Morocco (45%) z
Bolivia (47%) z
New Zealand (48%) z zz
Gabon (51%) z
Barbados (51%) z
Iran (52%) zz
Colombia (54%) zz
Kuwait (57%) z
Cameroon (66%) z
Nigeria (68%) z
Odds Ratio
0.50 1.0 2.0 4.0 8.0
Country (% frequent acetaminophen use)
Global Total (30%)
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Figure 3B: 
 
Taiwan (2%) z z
China (4%) z
Former Yugoslav Republic of Macedonia (FYROM) (7%) z
Hong Kong (7%) z
Lithuania (10%) z
Hungary (10%) zz
Estonia (13%) z
Uruguay (22%) z z
Canada (23%) z
India (24%) zzz zzz zz zz
Philippines (24%) z
Ethiopia (25%) z
Brazil (26%) zz zz
Portugal (29%) z zz
Peru (29%) z
Poland (30%) zz
Panama (30%) z
Indonesia (30%) z z
Mexico (30%) zz
Spain (31%) z z zz z zzz
Ecuador (32%) z
South Africa (36%) z
Venezuela (36%) z
Chile (40%) zz z
USA (42%) z
Syrian Arab Republic (43%) zz z
Morocco (45%) z
Bolivia (47%) z
New Zealand (48%) zz zz
Gabon (51%) z
Barbados (51%) z
Iran (52%) zz
Colombia (54%) zz
Kuwait (57%) z
Cameroon (66%) z
Nigeria (68%) z
Odds Ratio
0.50 1.0 2.0 4.0 8.0
Country (% frequent acetaminophen use)
Global Total (30%)
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When participants with asthma ever were excluded from the analysis, the use of 
acetaminophen was associated with a significantly increased risk of current symptoms of 
rhinoconjunctivitis with odds ratios of 1.35 (95% CI 1.26 to 1.45) and 2.29 (95% CI 2.13 
to 2.47) for medium and high acetaminophen use respectively.  Likewise, when 
participants with asthma ever were excluded from the analysis, there was an increased risk 
of current symptoms of eczema associated with the use of acetaminophen with odds ratios 
of 1.3 (95% CI 1.19 to 1.42) and 1.91 (95% CI 1.74 to 2.09) for medium and high 
acetaminophen use respectively. 
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